- Home
- GANX vs RDI Comparison
GANX vs RDI Comparison
Compare GANX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GANX | RDI |
|---|---|---|
| Founded | 2017 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.2M | 49.0M |
| IPO Year | 2021 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GANX | RDI |
|---|---|---|
| Price | $1.08 | $1.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.60 | N/A |
| AVG Volume (30 Days) | ★ 549.1K | 24.8K |
| Earning Date | 11-10-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 31.46 | ★ 60.76 |
| EPS | N/A | ★ N/A |
| Revenue | $55,180.00 | ★ $202,988,000.00 |
| Revenue This Year | N/A | $15.10 |
| Revenue Next Year | N/A | $4.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.94 | $0.94 |
| 52 Week High | $4.34 | $2.41 |
Technical Indicators
Market Signals| Indicator | GANX | RDI |
|---|---|---|
| Relative Strength Index (RSI) | 37.00 | 55.34 |
| Support Level | N/A | $1.64 |
| Resistance Level | $2.01 | $2.13 |
| Average True Range (ATR) | 0.10 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 38.42 | 86.21 |
Price Performance
Historical ComparisonAbout GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.